Introduction: A survey of 9,342 men aged 18-50 years was conducted in nine countries in four continents between April and June 2002. Results from Europe (Germany, France, Spain, Sweden), the U.S., Latin America (Mexico, Brasil, Argentina), and Indonesia will be presented. Patients and Methods: In the European countries and U.S. participants were chosen from males aged 18 to 50 years using existing panels (ACCESS panels, except for Sweden). In countries of Latin America and in Indonesia, the questionnaire was distributed by interviewers on the basis of a quota-sample. Interviewers were sent to certain areas, and recruited men of the required age group who were willing to participate in this study. When 1000 men were interviewed, the field work was regarded as complete in the respective country. Results: About 50 - 80% of men currently used contraceptive methods, and 55% - 78% decided together with their partner on the contraceptive method. 31% - 83% of the respondents were not willing to undergo vasectomy. The general acceptance of a new hormonal male fertility control was favourable: 49.2 % (USA), 57.6 % (Latin America), and 62.7 % (Europe). More than 93 % of men would seek advice on hormonal MFC from a physician. The “andrologist” (described as the specialist for men’s health care) ranked highest (86.4 %), followed by the urologist (80 %), the GP (73 %), and the gynecologist (61.8 %). The first choice would be a daily pill (64 %), followed by monthly injections (46 %), and a once per year implant (41 %). Efficacy of contraception (80-100%) and minimal side effects (80-100%) were considered as highly important. Conclusion: The overall acceptance of MFC was broad across various cultures.
Conflict of Interest: Employee Of Bayer Schering Pharma Ag
Financial Support/Funding: Study Supported By Schering Ag, Berlin, Germany
Sydney Australia, April 2007
more about this speaker
